How India Exports Imipenem to the World

In the United States, imipenem is marketed in combination with cilastatin and relebactam under the brand name Recarbrio, approved by the FDA for treating hospital-acquired pneumonia and other serious infections. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for imipenem-cilastatin combinations, indicating a competitive generic market. As of January 2026, there are no specific FDA import alerts targeting imipenem products from India. However, general import alerts, such as Import Alert 55-05 issued in November 2025, address concerns over microbiological contamination in drug products, underscoring the importance of stringent quality control measures for Indian exporters.

In the European Union, imipenem, in combination with cilastatin and relebactam, is authorized under the brand name Recarbrio. The European Medicines Agency (EMA) granted marketing authorization for Recarbrio on April 23, 2020, for treating infections caused by aerobic Gram-negative organisms in adults with limited treatment options. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring compliance with Good Manufacturing Practice (GMP) guidelines for marketing authorization.

Imipenem is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its critical role in healthcare. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, imipenem is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC), ensuring compliance with international standards and regulations.

The primary patents for imipenem have expired, leading to a competitive generic market with multiple manufacturers producing the drug. This has resulted in increased availability and affordability of imipenem globally.

In November 2025, the FDA issued Import Alert 55-05, focusing on the detention without physical examination of drug products due to potential microbiological contamination. This underscores the necessity for Indian exporters to maintain rigorous quality control measures to ensure compliance with international standards.

In January 2026, the EMA updated its guidelines on the use of carbapenem antibiotics, including imipenem, emphasizing the need for prudent use to combat antimicrobial resistance. This development may influence prescribing patterns and demand for imipenem in European markets.

These developments highlight the dynamic regulatory environment surrounding imipenem and the importance of continuous monitoring to ensure compliance and market competitiveness.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs), with imports accounting for over 70% of bulk drug requirements. This dependency poses significant risks, as evidenced by supply chain disruptions in recent years. For instance, in July 2018, environmental regulations led to the shutdown of several Chinese chemical plants, causing a surge in raw material prices and supply shortages for Indian manufacturers.

To mitigate such vulnerabilities, the Indian government launched the Production Linked Incentive (PLI) Scheme for Bulk Drugs in July 2020, aiming to boost domestic manufacturing of critical KSMs, DIs, and APIs. By September 2025, the scheme had facilitated the creation of production capacities for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore.

Our proprietary trade data indicates that the top five exporters of Imipenem from India account for 79.7% of the total export value, with VENUS REMEDIES LIMITED alone contributing 40.6%. This high supplier concentration exposes the supply chain to significant risks, as disruptions affecting these key players could severely impact global availability.

The PLI Scheme for Pharmaceuticals, initiated in March 2021, aims to diversify and strengthen the supplier base by incentivizing domestic production of high-value pharmaceutical products. As of September 2025, the scheme had attracted a committed investment of ₹17,275 crore, surpassing the initial target, and had already achieved an actual investment of ₹40,890 crore.

Geopolitical tensions and shipping disruptions pose additional risks to the Imipenem supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for pharmaceutical exports; any instability in these regions can lead to delays and increased shipping costs. Furthermore, ongoing US-China trade tensions have the potential to disrupt the supply of essential raw materials, exacerbating existing vulnerabilities.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various antibiotics in recent years, underscoring the fragility of global pharmaceutical supply chains. For example, in June 2025, the FDA reported shortages of several antibiotics due to supply chain disruptions, highlighting the need for robust risk mitigation strategies.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Imipenem and its raw materials to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Leverage government initiatives like the PLI Scheme to boost domestic manufacturing capacities for critical APIs and KSMs.

• Strengthen Regulatory Compliance: Ensure that all suppliers adhere to stringent quality and environmental standards to prevent disruptions due to regulatory non-compliance.

• Develop Contingency Plans: Establish comprehensive contingency plans to address potential geopolitical and shipping disruptions, including alternative transportation routes and strategic stockpiling.

• Monitor Global Developments: Continuously monitor geopolitical events and trade policies that could impact the pharmaceutical supply chain, enabling proactive risk management.

RISK_LEVEL: MEDIUM